This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Tecarfarin
DrugBank Accession Number
DB12823
Background

Tecarfarin has been used in trials studying the prevention of Thrombosis and Thromboembolism.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 460.328
Monoisotopic: 460.074542529
Chemical Formula
C21H14F6O5
Synonyms
  • Tecarfarin
External IDs
  • Ati 5923
  • ATI-5923

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetohexamideThe therapeutic efficacy of Acetohexamide can be increased when used in combination with Tecarfarin.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be increased when used in combination with Tecarfarin.
DexmethylphenidateThe serum concentration of the active metabolites of Tecarfarin can be increased when Tecarfarin is used in combination with Dexmethylphenidate.
DoxycyclineThe therapeutic efficacy of Tecarfarin can be increased when used in combination with Doxycycline.
GliclazideThe therapeutic efficacy of Gliclazide can be increased when used in combination with Tecarfarin.
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Tecarfarin.
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Tecarfarin.
GliquidoneThe therapeutic efficacy of Gliquidone can be increased when used in combination with Tecarfarin.
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Tecarfarin.
LepirudinThe risk or severity of bleeding can be increased when Tecarfarin is combined with Lepirudin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 4-hydroxycoumarins. These are coumarins that contain one or more hydroxyl groups attached to C4-position the coumarin skeleton.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Coumarins and derivatives
Sub Class
Hydroxycoumarins
Direct Parent
4-hydroxycoumarins
Alternative Parents
Benzoic acid esters / 1-benzopyrans / Benzoyl derivatives / Pyranones and derivatives / Vinylogous acids / Heteroaromatic compounds / Lactones / Carboxylic acid esters / Oxacyclic compounds / Organooxygen compounds
show 4 more
Substituents
1-benzopyran / 4-hydroxycoumarin / Alkyl fluoride / Alkyl halide / Aromatic heteropolycyclic compound / Benzenoid / Benzoate ester / Benzoic acid or derivatives / Benzopyran / Benzoyl
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
WN1479YT50
CAS number
867257-26-9
InChI Key
QFLNTQDOVCLQKW-UHFFFAOYSA-N
InChI
InChI=1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
IUPAC Name
1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yl 4-[(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl]benzoate
SMILES
CC(OC(=O)C1=CC=C(CC2=C(O)C3=CC=CC=C3OC2=O)C=C1)(C(F)(F)F)C(F)(F)F

References

General References
Not Available
PubChem Compound
54718618
PubChem Substance
347828992
ChemSpider
26467760
ChEMBL
CHEMBL2105664
Wikipedia
Tecarfarin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentThromboembolism / Thrombosis1
2CompletedTreatmentAtrial Fibrillation1
2, 3Unknown StatusTreatmentAtrial Fibrillation / Atrial Flutter / Cardiomyopathy / Myocardial Infarction / Venous Thromboembolism Diseases1
1CompletedBasic SciencePharmacokinetic and Pharmacodynamic Profile of Tecarfarin1
1Enrolling by InvitationBasic ScienceHealthy Chinese Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0026 mg/mLALOGPS
logP4.71ALOGPS
logP5.26Chemaxon
logS-5.2ALOGPS
pKa (Strongest Acidic)5.13Chemaxon
pKa (Strongest Basic)-6.7Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area72.83 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity99.73 m3·mol-1Chemaxon
Polarizability37.11 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 21, 2016 00:31 / Updated at February 21, 2021 18:54